Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04581902 · ClinicalTrials.gov registry record · NA

Biomarkers of Depression and Treatment Response

A NA study of Depressive Disorder, Major, sponsored by University of California, San Francisco.

Recruiting
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT04581902 is a NA study of Depressive Disorder, Major that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 50 participants, below the 241-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04581902, a NA study of Depressive Disorder, Major, is actively recruiting participants, sponsored by University of California, San Francisco.

RECRUITING
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

This study is a stratified, parallel-group, single-center study utilizing multimodal imaging techniques to identify biomarkers for Major Depressive Disorder (MDD). The study goal is to identify biomarkers for MDD and treatment response that can be implemented in clinical diagnosis and care as valid and reliable measures, through monitoring neurophysiological and electrophysiological changes across the course of transcranial magnetic stimulation (TMS) treatment.

Conditions Studied

Interventions

  • DEVICE rTMS therapy

Study Locations (1)

California

  • University of California, San Francisco - San Francisco

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2020-12-01
Est. Completion 2027-09
Phase NA

What the Registry Record Tells You About NCT04581902

The ClinicalTrials.gov registry entry for NCT04581902 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 241-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (79% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Depressive Disorder, Major appearing as the primary indexed condition, and to 1 intervention - of which rTMS therapy is the first listed.

NCT04581902 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT04581902 about?

NCT04581902 is a clinical study titled "Biomarkers of Depression and Treatment Response". This study is a stratified, parallel-group, single-center study utilizing multimodal imaging techniques to identify biomarkers for Major Depressive Disorder (MDD). The study goal is to identify biomarkers for MDD and treatment response that can be implemented in clinical diagnosis and care as valid ...

What is the current status of trial NCT04581902?

This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2020-12-01. Estimated completion is 2027-09.

What conditions does trial NCT04581902 study?

This clinical trial studies the following conditions: Depressive Disorder, Major.

What interventions are being tested in trial NCT04581902?

The interventions under investigation include: rTMS therapy (DEVICE).

Who is sponsoring clinical trial NCT04581902?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04581902 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depressive Disorder, Major

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.